Author

Natalie E. Castellana

Abterra Biosciences (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:proteomics· 2 Research Focus:benchmarking· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Anand D. PateliD· 2 shared Stefano R. BonissoneiD· 2 shared Geir Kjetil SandveiD· 1 shared Igor SnapkoviD· 1 shared Jan Terje AnderseniD· 1 shared Khang Lê QuýiD· 1 shared Konstantinos KalogeropoulosiD· 1 shared Maria ChernigovskayaiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Anand D. PatelORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologyCell SystemsPeer-reviewedNov 1, 2025

Systematic benchmarking of mass spectrometry-based antibody sequencing reveals methodological biases

Maria Chernigovskaya, Khang Lê Quý, Maria Stensland…·Victor Greiff

This study benchmarks mass spectrometry-based antibody sequencing methods, revealing biases related to sequence, concentration, protease, and bioinformatics tools.

2 citations

proteomicsstatistical model

𝕏 PostBluesky

ImmunologyFrontiers in ImmunologyPeer-reviewedFeb 25, 2025

Serum proteomics reveals high-affinity and convergent antibodies by tracking SARS-CoV2 hybrid immunity to emerging variants of concern

Anand D. Patel, Thiago Lima, Richard Carson…·Natalie E. Castellana

The paper identifies high-affinity anti-SARS-CoV-2 antibodies in serum and B cells from donors with hybrid immunity, showing convergence and cross-reactivity against emerging variants.

DOI 10.3389/fimmu.2025.1509888

humanproteomics

𝕏 PostBluesky